Literature DB >> 22110432

Early stages of calciphylaxis: are skin biopsies the answer?

Joerg Latus1, Martin Kimmel, German Ott, Evelyn Ting, M Dominik Alscher, Niko Braun.   

Abstract

Calciphylaxis, nowadays called calcific uremic arteriolopathy (CUA), is a rare but life-threatening syndrome characterized by systemic medial calcification and arterial occlusion of the arterioles, leading to skin necrosis. Actually, the pathogenesis of CUA is complex and poorly understood. The vast majority of published cases presented with ulcers. We present a 71-year-old male who was referred to the Nephrology Department for evaluation and therapy for refractory edema of both legs. There were no subcutaneous plaques, ulcers or other focal lesions. We performed a deep skin biopsy of the thigh. After the biopsy, the patient developed necrosis around the sampling location. Diagnosing CUA in the early stages of the disease, however, is challenging. Should a skin biopsy be performed in the early stages of CUA in patients without ulcerations, knowing the risk of inducing ulcerations, or should an intensive treatment - after considering clinical manifestations, other noninvasive diagnostic tools (bone scan, X-ray mammography technique) and laboratory tests - be started? Although there are no specific diagnostic laboratory tests for CUA and the clinical manifestations of CUA are similar to those of other disorders, a skin biopsy is not routinely recommended to confirm the diagnosis of early-stage calciphylaxis.

Entities:  

Keywords:  Calcific uremic arteriolopathy; Calciphylaxis; Deep skin biopsy; Necrosis

Year:  2011        PMID: 22110432      PMCID: PMC3219451          DOI: 10.1159/000333007

Source DB:  PubMed          Journal:  Case Rep Dermatol        ISSN: 1662-6567


Introduction

Calciphylaxis, nowadays called calcific uremic arteriolopathy (CUA), is a rare but life-threatening syndrome characterized by systemic medial calcification and arterial occlusion of the arterioles, leading to skin necrosis. CUA characteristically occurs in patients with end-stage renal disease and secondary hyperparathyroidism or those who have recently received a renal transplant; however, it has also been described in patients with normal renal function and calcium/phosphate metabolism [1, 2, 3]. There is an increasing prevalence of this condition, as high as 4.1%, in patients with end-stage renal disease [4]. The most common cause in nonuremic patients is primary hyperparathyroidism [5]. Actually, the pathogenesis of CUA is complex and poorly understood. The vast majority of published cases presented with ulcers.

Case Report

A 71-year-old Caucasian male, with a history of hypertension, coronary artery disease, and end-stage renal disease caused by nephrosclerosis, who had been on peritoneal dialysis for the previous 9 months, was referred to the Nephrology Department for evaluation and therapy for refractory edema of both legs. Clinical examination showed erythema, thickening of the skin and symmetric painful swelling extending from both feet up to the groin. There were no subcutaneous plaques, ulcers or other focal lesions (fig. ). An MRI was performed to facilitate biopsy planning and to rule out dermatomyositis, nephrogenic systemic fibrosis and fasciitis. Findings were unspecific concerning edema and signs of fasciitis; no focal enhancement was found. A deep skin biopsy of the thigh was also performed. Biopsy findings are shown in fig. 1b.
Fig. 1

a The patient's left leg, on admission, with edema and erythema but without subcutaneous plaques, ulcers or other focal lesions. b Histology of the skin biopsy shows concentric calcification of the media layer of small arteriolar vessels, subintimal fibrosis and, consequently, arterial occlusion (von Kossa stain; ×400). There were no signs of underlying vasculitis. c The necrotic area expanded considerably and reached a maximum of 220 mm two weeks after the skin biopsy.

After diagnosing calciphylaxis, the patient was switched to daily hemodialysis. Treatment with vitamin D, calcium-containing phosphorous binders and phenprocoumon was stopped, and a regimen consisting of cinacalcet, vitamin K and sodium thiosulfate therapy was immediately started. Two days after the biopsy, the patient developed necrosis around the sampling location. Over the next 2 weeks, the extent of the necrosis increased considerably and reached a maximum extension of 220 mm (fig. 1c). Daily surgical consultations guaranteed optimal wound care. Despite a complex and multidisciplinary approach, the deep ulcer did not heal and new focal skin lesions came up. It was not until after several months of intense therapy that the disease process was stopped and a slight improvement was noticed.

Discussion

Clinical presentation of late-stage CUA is unique and a skin biopsy is often not required. The diagnosis of CUA in the early stages of the disease, however, is challenging. For instance, CUA can be mistaken for nephrogenic systemic fibrosis which can manifest as erythematous papules that coalesce into erythematous to brawny plaques, with the skin involved becoming woody and thickened in texture [6]. The importance of obtaining a skin biopsy to differentiate, for example, between these two disorders is essential and knowledge of the exact tissue histology is helpful in confirming a strong clinical suspicion. Should a skin biopsy be performed in the early stages of CUA in patients without ulcerations, knowing the risk of inducing ulcerations, or should an intensive treatment – after considering clinical manifestations, other noninvasive diagnostic tools (bone scan, X-ray mammography technique) and laboratory tests – be started? This question is not easily answered. Definitive criteria to diagnose CUA are surely needed in order to avoid inconclusive skin biopsies as well as the risk of inducing ulcerations stemming from local tissue trauma following a skin biopsy. Skin biopsy results are helpful in cases of doubt. Although there are no specific diagnostic laboratory tests for CUA and the clinical manifestations of CUA are similar to those of other disorders, a skin biopsy is not routinely recommended to confirm the diagnosis of early-stage calciphylaxis.

Disclosure Statement

The authors report no conflicts of interest.
  6 in total

Review 1.  Nephrogenic fibrosing dermopathy: the first 6 years.

Authors:  Shawn E Cowper
Journal:  Curr Opin Rheumatol       Date:  2003-11       Impact factor: 5.006

Review 2.  Calcified subcutaneous arterioles with infarcts of the subcutis and skin ("calciphylaxis") in chronic renal failure.

Authors:  D T Janigan; D J Hirsch; G A Klassen; A S MacDonald
Journal:  Am J Kidney Dis       Date:  2000-04       Impact factor: 8.860

Review 3.  Calciphylaxis in a patient with Crohn's disease in the absence of end-stage renal disease.

Authors:  Y M Barri; G S Graves; J P Knochel
Journal:  Am J Kidney Dis       Date:  1997-05       Impact factor: 8.860

4.  Calciphylaxis in patients on hemodialysis: a prevalence study.

Authors:  M Angelis; L L Wong; S A Myers; L M Wong
Journal:  Surgery       Date:  1997-12       Impact factor: 3.982

5.  Lethal post-transplantation calcinosis.

Authors:  L J Perloff; R K Spence; R A Grossman; C F Barker
Journal:  Transplantation       Date:  1979-01       Impact factor: 4.939

Review 6.  Calciphylaxis from nonuremic causes: a systematic review.

Authors:  Sagar U Nigwekar; Myles Wolf; Richard H Sterns; John K Hix
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 8.237

  6 in total
  4 in total

1.  Prevalence and Clinical Characteristics of Calciphylaxis in Chinese Hemodialysis Patients.

Authors:  Yuqiu Liu; Canlin Yang; Xin Yang; Xiaotong Xie; Hong Liu; Liuping Zhang; Jianming Ye; Dongsheng Jiang; Xiaoliang Zhang; Bicheng Liu
Journal:  Front Med (Lausanne)       Date:  2022-06-10

2.  Successful treatment of calciphylaxis by a multidisciplinary approach.

Authors:  Lisa Borges; Pedro Rosa; Emanuel Dias; Isabel Cássio
Journal:  BMJ Case Rep       Date:  2014-07-17

Review 3.  Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease-mineral and bone disorder.

Authors:  Vincent M Brandenburg; Smeeta Sinha; Paula Specht; Markus Ketteler
Journal:  Pediatr Nephrol       Date:  2014-01-29       Impact factor: 3.714

4.  A case report of severe calciphylaxis - suggested approach for diagnosis and treatment.

Authors:  Margret Patecki; Gabriele Lehmann; Jan Hinrich Bräsen; Jessica Schmitz; Anna Bertram; Lars Daniel Berthold; Hermann Haller; Wilfried Gwinner
Journal:  BMC Nephrol       Date:  2017-04-21       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.